Atripla Is More Than Just the Sum of Its Three PartsNew study: People with HIV who take the once-a-day combination pill of tenofovir+emtricitabine+efavirenz are less likely to develop drug resistance and take longer to reach virologic failure (if it occurs) than those who take an equivalent combo of 3 separate pills.
These findings underline the potential risks of prescribing Atripla’s individual components separately to save money, which experts say could happen as the ARVs lose their patents and generics enter the market.

Atripla Is More Than Just the Sum of Its Three Parts

New study: People with HIV who take the once-a-day combination pill of tenofovir+emtricitabine+efavirenz are less likely to develop drug resistance and take longer to reach virologic failure (if it occurs) than those who take an equivalent combo of 3 separate pills.

These findings underline the potential risks of prescribing Atripla’s individual components separately to save money, which experts say could happen as the ARVs lose their patents and generics enter the market.